PUNE, India, April 13, 2016 /PRNewswire/ --

Global Status Epilepticus - Pipeline Review, H1 2016 report provides an overview and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H1 2016 pipeline review of Status Epilepticus with 19 market data tables and 12 figures, spread across 58 pages is available at http://www.reportsnreports.com/reports/516187-status-epilepticus-pipeline-review-h1-2016.html   

Company Profiles discussed in this report includes Marinus Pharmaceuticals, Inc., RODES Inc. and Sage Therapeutics, Inc. Drugs Profiles discussed in this research includes AMPX-0079, fosphenytoin sodium, ganaxolone, SAGE-217, SAGE-689, sepranolone, Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus and TG-4155.

This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Status Epilepticus and reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Status Epilepticus therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Status Epilepticus.

Order a Purchase copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=516187  

List of Tables 

Number of Products under Development for Status Epilepticus, H1 2016

Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Status Epilepticus - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016

Status Epilepticus - Pipeline by RODES Inc., H1 2016

Status Epilepticus - Pipeline by Sage Therapeutics, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Status Epilepticus Therapeutics - Recent Pipeline Updates, H1 2016

Status Epilepticus - Dormant Projects, H1 2016

Another newly published market research report titled on Charcot-Marie-Tooth Disease - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Charcot-Marie-Tooth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Charcot-Marie-Tooth Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Charcot-Marie-Tooth Disease Pipeline market research report of 56 pages is available at http://www.reportsnreports.com/reports/516210-charcot-marie-tooth-disease-pipeline-review-h1-2016.html   

Explore more reports on Pharmaceuticals

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+/Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

SOURCE ReportsnReports